摘要:
Compositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and/or monitoring liver cancers using the expressing of CDH17 involve detecting and/or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor.
摘要:
Compositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and/or monitoring liver cancers using the expressing of CDH17 involve detecting and/or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor.
摘要:
Described herein are methods for manipulating GEP and/or drug transporters (e.g., ABCB5 and/or ABCF1) on a cell, as well as related products. Also described herein are methods for treating cancer cells using GEP and/or drug transporter and/or their binding molecules and suppression thereof. Methods of cancer treatment targeting the GEP and/or drug transporters, alone or in combination with chemotherapy are also described herein. Also provided herein are sets of markers whose expression patterns can be used to differentiate clinical conditions, such as high or low levels of GEP and drug transporters. Based on the levels of GEP and drug transporters, the likelihood of cancer recurrences, drug sensitivity, and prognosis can be determined. Methods of classifying and treating patients based on the prognosis are also provided herein.
摘要:
This invention provides methods for detecting serum GEP level. This invention further provides methods for determining whether a subject is afflicted with Hepatocellular carcinoma (HCC) by measuring serum GEP level. In another embodiment, this invention provides methods for the suppression of HCC growth and progression both in vitro and in vivo by treating a patient with anti-GEP monoclonal antibody A23.
摘要:
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要:
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要:
This invention provides a composition comprising the following polynucleotide probes: IL7R (AA485865) (SEQ ID NO:7), NDRGI (AA486403) (SEQ ID NO:8), EST1 (H50345) (SEQ ID NO:9), TRPC1 (AA017132) (SEQ ID NO:10), GFRA1 (AA512935) (SEQ ID NO:11), EST2 (AA454543) (SEQ ID NO:12), CLDN10 (R54559) (SEQ ID NO:13), DNALI1 (R93087) (SEQ ID NO:14), RBP5 (AA453198) (SEQ ID NO:15), EST3 (AA621761) (SEQ ID NO:16), EST4 (N63706) (SEQ ID NO:17), PCOLCE (AA670200) (SEQ ID NO:18), TDO2 (T72398) (SEQ ID NO:19), EST5 (T47454) (SEQ ID NO:20), HIST1H2BD (N33927) (SEQ ID NO:21), PXMP2 (N70714) (SEQ ID NO:22), ACAS2 (AA455146) (SEQ ID NO:23), ANAPC7 (T68445) (SEQ ID NO:24), EST6 (AA576580) (SEQ ID NO:25), RBP5 (N92148) (SEQ ID NO:26), ANXAI (H63077) (SEQ ID NO:27), CKB (AA894557) (SEQ ID NO:28), ITGBL1 (N52533) (SEQ ID NO:29), KPNA2 (AA676460) (SEQ ID NO:30), EST7 (W90740) (SEQ ID NO:31) and MEG3 (W85841) (SEQ ID NO:32). This invention further provides methods for determining the likelihood of recurrence of hepatocellular carcinoma (HCC) in a subject afflicted with HCC, for determining the likelihood of death of a subject afflicted with HCC or for determining whether to administer adjuvant therapy.
摘要翻译:本发明提供包含以下多核苷酸探针的组合物:IL7R(AA485865)(SEQ ID NO:7),NDRGI(AA486403)(SEQ ID NO:8),EST1(H50345)(SEQ ID NO:9),TRPC1(AA017132 )(SEQ ID NO:10),GFRA1(AA512935)(SEQ ID NO:11),EST2(AA454543)(SEQ ID NO:12),CLDN10(R54559)(SEQ ID NO:13),DNALI1(R93087)( SEQ ID NO:14),RBP5(AA453198)(SEQ ID NO:15),EST3(AA621761)(SEQ ID NO:16),EST4(N63706)(SEQ ID NO:17),PCOLCE(AA670200) (SEQ ID NO:20),HIST1H2BD(N33927)(SEQ ID NO:21),PXMP2(N70714)(SEQ ID NO:18),TD02(T72398)(SEQ ID NO:19),EST5(T47454) 22),ACAS2(AA455146)(SEQ ID NO:23),ANAPC7(T68445)(SEQ ID NO:24),EST6(AA576580)(SEQ ID NO:25),RBP5(N92148)(SEQ ID NO:26) ,ANXAI(H63077)(SEQ ID NO:27),CKB(AA894557)(SEQ ID NO:28),ITGBL1(N52533)(SEQ ID NO:29),KPNA2(AA676460)(SEQ ID NO:30),EST7 (W90740)(SEQ ID NO:31)和MEG3(W85841)(SEQ ID NO:32)。 本发明还提供了确定患有HCC的受试者中肝细胞癌(HCC)复发的可能性的方法,以确定患有HCC的受试者的死亡的可能性或用于确定是否施用辅助治疗。
摘要:
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要:
This invention provides a composition comprising the following polynucleotide probes: IL7R (AA485865) (SEQ ID NO:7), NDRGI (AA486403) (SEQ ID NO:8), EST1 (H50345) (SEQ ID NO:9), TRPC1 (AA017132) (SEQ ID NO:10), GFRA1 (AA512935) (SEQ ID NO:11), EST2 (AA454543) (SEQ ID NO:12), CLDN10 (R54559) (SEQ ID NO:13), DNALI1 (R93087) (SEQ ID NO:14), RBP5 (AA453198) (SEQ ID NO:15), EST3 (AA621761) (SEQ ID NO:16), EST4 (N63706) (SEQ ID NO:17), PCOLCE (AA670200) (SEQ ID NO:18), TDO2 (T72398) (SEQ ID NO:19), EST5 (T47454) (SEQ ID NO:20), HIST1H2BD (N33927) (SEQ ID NO:21), PXMP2 (N70714) (SEQ ID NO:22), ACAS2 (AA455146) (SEQ ID NO:23), ANAPC7 (T68445) (SEQ ID NO:24), EST6 (AA576580) (SEQ ID NO:25), RBP5 (N92148) (SEQ ID NO:26), ANXAI (H63077) (SEQ ID NO:27), CKB (AA894557) (SEQ ID NO:28), ITGBL1 (N52533) (SEQ ID NO:29), KPNA2 (AA676460) (SEQ ID NO:30), EST7 (W90740) (SEQ ID NO:31) and MEG3 (W85841) (SEQ ID NO:32). This invention further provides methods for determining the likelihood of recurrence of hepatocellular carcinoma (HCC) in a subject afflicted with HCC, for determining the likelihood of death of a subject afflicted with HCC or for determining whether to administer adjuvant therapy.
摘要翻译:本发明提供包含以下多核苷酸探针的组合物:IL7R(AA485865)(SEQ ID NO:7),NDRGI(AA486403)(SEQ ID NO:8),EST1(H50345)(SEQ ID NO:9),TRPC1(AA017132 )(SEQ ID NO:10),GFRA1(AA512935)(SEQ ID NO:11),EST2(AA454543)(SEQ ID NO:12),CLDN10(R54559)(SEQ ID NO:13),DNALI1(R93087)( SEQ ID NO:14),RBP5(AA453198)(SEQ ID NO:15),EST3(AA621761)(SEQ ID NO:16),EST4(N63706)(SEQ ID NO:17),PCOLCE(AA670200) (SEQ ID NO:20),HIST1H2BD(N33927)(SEQ ID NO:21),PXMP2(N70714)(SEQ ID NO:18),TD02(T72398)(SEQ ID NO:19),EST5(T47454) 22),ACAS2(AA455146)(SEQ ID NO:23),ANAPC7(T68445)(SEQ ID NO:24),EST6(AA576580)(SEQ ID NO:25),RBP5(N92148)(SEQ ID NO:26) ,ANXAI(H63077)(SEQ ID NO:27),CKB(AA894557)(SEQ ID NO:28),ITGBL1(N52533)(SEQ ID NO:29),KPNA2(AA676460)(SEQ ID NO:30),EST7 (W90740)(SEQ ID NO:31)和MEG3(W85841)(SEQ ID NO:32)。 本发明还提供了确定患有HCC的受试者中肝细胞癌(HCC)复发的可能性的方法,以确定患有HCC的受试者的死亡的可能性或用于确定是否施用辅助治疗。
摘要:
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.